{"member_organisations": "", "identification_number": "787298132601-52", "fields_of_interest": "Research and innovation, Public Health", "head_office_address": "Daval International Ltd 114a Cromwell Road Kensington", "full_time_equivalent_fte": "1,25", "person_with_legal_responsibility": "Kevin Norville", "industry_forums": "", "grants": "", "inter_groups": "", "eu_initiatives": "Daval International will be meeting with various EU Institutions and agencies to seek clarity on EU initiatives, policies and legislation relating to their project. This will include issues surrounding the conducting of clinical trials for Alzheimer's disease.", "level_of_interest": "global", "organisation_name": "Daval International Limited", "belgium_office_post_code": "", "number_of_persons_involved": "3", "person_in_charge_of_eu_relations": "Kevin Norville", "section": "II - In-house lobbyists and trade/business/professional associations", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "", "no_geo_reference": true, "persons_accredited_for_access_to_european_parliament_premises": "", "registration_date": "17/09/2018", "estimate_of_costs_absolute_amount": "", "website_address": "http://www.davalinternational.com", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "London", "membership": "The Association of the British Pharmaceutical Industry (ABPI) \u2013 abpi@apbi.org.uk", "head_office_post_code": "SW7 4ES", "position": "CEO", "financial_year_start_date": "01/11/2016", "head_office_country": "United Kingdom", "number_of_ep_accredited_persons": "", "relevant_communication": "None", "financial_year_end_date": "01/10/2017", "estimate_of_costs_as_a_range": "50000-99999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporation", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "Daval International Limited is a UK-based biotechnology company formed in 2000 and focused on the development and delivery of novel and distinctive treatments for serious unmet medical conditions. Daval was accepted as a member of the UK\u2019s Association of the British Pharmaceutical Industry (ABPI) in December 2007 and adheres to the APBI's Code of Practice. Daval has developed AIMSPRO, a potent, anti-inflammatory, natural, biological therapy that has proven capacity to reduce inflammation. Daval believes that, in AIMSPRO, they may have the next efficacious Alzheimer's disease medication which has a decade-long proven safety record in human patients.", "belgium_office_city": "", "head_office_phone": "(+44)8451303014"}